FDA Announces Draft Guidance for Waivers of Bioequivalence for Generic Soluble Powder Oral Dosage Form Products

Summary

The FDA has released a draft guidance outlining procedures for reviewing requests to waive in vivo bioequivalence testing for generic soluble powder oral dosage form products and Type A medicated articles, aiming to streamline the review process for these types of generic drugs.